Arrowstreet Capital Limited Partnership Boosts Holdings in Becton, Dickinson and Company $BDX

Arrowstreet Capital Limited Partnership increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 127.0% during the 4th quarter, Holdings Channel reports. The institutional investor owned 839,854 shares of the medical instruments supplier’s stock after purchasing an additional 469,846 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Becton, Dickinson and Company were worth $162,990,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Becton, Dickinson and Company by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after buying an additional 4,223,149 shares during the last quarter. State Street Corp lifted its position in shares of Becton, Dickinson and Company by 0.8% during the fourth quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock worth $2,714,871,000 after purchasing an additional 116,737 shares in the last quarter. First Eagle Investment Management LLC lifted its position in shares of Becton, Dickinson and Company by 16.5% during the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock worth $2,260,139,000 after purchasing an additional 1,651,592 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in Becton, Dickinson and Company by 3.7% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 9,486,694 shares of the medical instruments supplier’s stock valued at $1,841,083,000 after buying an additional 336,110 shares during the period. Finally, Geode Capital Management LLC grew its stake in Becton, Dickinson and Company by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 6,885,361 shares of the medical instruments supplier’s stock worth $1,331,165,000 after purchasing an additional 53,884 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BDX has been the topic of several recent research reports. Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a report on Tuesday, April 14th. TD Cowen lowered their price objective on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a research report on Monday, May 4th. Wells Fargo & Company upped their target price on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. The Goldman Sachs Group decreased their price target on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday, May 27th. Finally, BofA lowered their price target on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus price target of $182.73.

Insider Transactions at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $151.48, for a total value of $166,628.00. Following the sale, the executive vice president owned 14,272 shares of the company’s stock, valued at $2,161,922.56. This represents a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 4,013 shares of company stock valued at $593,434. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Trading Down 0.4%

BDX opened at $145.61 on Tuesday. The business’s 50 day moving average is $149.82 and its two-hundred day moving average is $173.58. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The firm has a market cap of $40.12 billion, a price-to-earnings ratio of 36.86, a price-to-earnings-growth ratio of 10.35 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. During the same quarter in the previous year, the firm posted $3.35 EPS. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, research analysts predict that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.9%. Becton, Dickinson and Company’s dividend payout ratio is 106.33%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.